PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours
Authors
Keywords
-
Journal
ENDOCRINE PATHOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-11
DOI
10.1007/s12022-021-09673-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Human CD4+ T cell subsets differ in their abilities to cross endothelial and epithelial brain barriers in vitro
- (2020) Hideaki Nishihara et al. Fluids and Barriers of the CNS
- Utility of GATA-3 Expression in the Analysis of Pituitary Neuroendocrine Tumour (PitNET) Transcription Factors
- (2020) John Turchini et al. ENDOCRINE PATHOLOGY
- Cytokeratin Profiles in Pituitary Neuroendocrine Tumors
- (2020) Sylvia L. Asa et al. HUMAN PATHOLOGY
- Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study
- (2020) Nazanin Majd et al. Journal for ImmunoTherapy of Cancer
- Immune checkpoint inhibitor-induced colitis: A comprehensive review
- (2019) Aniruddh Som et al. World Journal of Clinical Cases
- Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases
- (2019) Dennis P. O’Malley et al. MODERN PATHOLOGY
- An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors
- (2019) Omalkhaire M. Alshaikh et al. ENDOCRINE PATHOLOGY
- Non-functioning pituitary adenomas: indications for pituitary surgery and post-surgical management
- (2019) Daniela Esposito et al. Pituitary
- The Treatment of Refractory Pituitary Adenomas
- (2019) Congxin Dai et al. Frontiers in Endocrinology
- Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience
- (2019) G Giuffrida et al. Endocrine Connections
- MANAGEMENT OF ENDOCRINE DISEASE: Immune check point inhibitors-induced hypophysitis
- (2019) Frédérique Albarel et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016
- (2018) Ann McCormack et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- The expression profile of PD-L1 and CD8+ lymphocyte in pituitary adenomas indicating for immunotherapy
- (2018) Peng-fei Wang et al. JOURNAL OF NEURO-ONCOLOGY
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
- (2018) Romualdo Barroso-Sousa et al. JAMA Oncology
- Marked response of a hypermutated adrenocorticotropic hormone-secreting pituitary carcinoma to ipilimumab and nivolumab
- (2018) Andrew L Lin et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal
- (2017) S L Asa et al. ENDOCRINE-RELATED CANCER
- The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma
- (2017) Emma S Scott et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Diagnosis and Treatment of Pituitary Adenomas
- (2017) Mark E. Molitch JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Outcome of Nonfunctioning Pituitary Adenomas That Regrow After Primary Treatment: A Study From Two Large UK Centers
- (2017) Metaxia Tampourlou et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability
- (2017) Hans Brunnström et al. MODERN PATHOLOGY
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
- (2017) Sydney R. Gordon et al. NATURE
- Histopathological classification of non-functioning pituitary neuroendocrine tumors
- (2017) Emilija Manojlovic-Gacic et al. Pituitary
- Why anti-PD1/PDL1 therapy is so effective? Another piece in the puzzle
- (2017) Antonio Marchetti et al. Journal of Thoracic Disease
- Revisitation of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects
- (2016) Giuseppe Bellastella et al. Pituitary
- Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors
- (2016) Yu Mei et al. Oncotarget
- Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide
- (2015) Daniel Bengtsson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina
- (2015) Oscar D. Bruno et al. International Journal of Endocrinology
- Succinate Dehydrogenase Deficiency Is Rare in Pituitary Adenomas
- (2014) Anthony J. Gill et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment
- (2012) Gérald Raverot et al. CLINICAL ENDOCRINOLOGY
- Capture, crawl, cross: the T cell code to breach the blood–brain barriers
- (2012) Britta Engelhardt et al. TRENDS IN IMMUNOLOGY
- Radiation Therapy in the Management of Pituitary Adenomas
- (2011) Jay S. Loeffler et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Natural History of Nonfunctioning Pituitary Adenomas and Incidentalomas: A Systematic Review and Metaanalysis
- (2011) M. Mercè Fernández-Balsells et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline
- (2011) Pamela U. Freda et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Temozolomide Treatment for Aggressive Pituitary Tumors: Correlation of Clinical Outcome with O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation and Expression
- (2010) Zachary M. Bush et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pituitary incidentalomas
- (2009) Mark E. Molitch BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now